Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet–cold pattern
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03745-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Kenichi Matsushita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tokyo CCU Network Scientific Committee, Tokyo, Japan. kenichi-matsushita@umin.ac.jp. Hauptthemen laut MEDLINE: Heart Failure, Antidiuretic Hormone Receptor Antagonists, Tolvaptan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Tokyo Metropolitan Government, Vehicle Racing Commemorative Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
PURPOSE: This study investigated whether the oral vasopressin V2 receptor antagonist tolvaptan has beneficial effects on mortality in real-world congestive heart failure (CHF) patients with hypoperfusion (i.e. the wet-cold pattern), from the viewpoint of cardiorenal syndrome. METHODS: Data on 5511 consecutive CHF patients were extracted from the Tokyo CCU Network data registry. Congestion and hypoperfusion were defined by Nohria-Stevenson clinical profiles at the time of hospitalization. Propensity scores for tolvaptan use were calculated for each patient and used to assemble two matched cohorts of patients receiving tolvaptan or not in the CHF with and without hypoperfusion groups. RESULTS: Of the entire study cohort, 1073 patients (19%) had CHF with hypoperfusion (i.e. the wet-cold pattern). In-hospital mortality was significantly higher for CHF patients with than without hypoperfusion (log-rank, P < 0.001). The rate of tolvaptan use did not differ significantly between CHF patients with and without hypoperfusion (15% vs. 14%, respectively; P = 0.7848). In the propensity-matched CHF with hypoperfusion cohort, there was a significant association between the use of tolvaptan and a reduction in in-hospital mortality (log-rank, P = 0.0052). Conversely, in the matched CHF without hypoperfusion cohort, tolvaptan use was not associated with in-hospital mortality (log-rank, P = 0.4417). CONCLUSION: There was a significant association between the use of tolvaptan and a reduction in in-hospital mortality in CHF patients with, but not without, hypoperfusion. These findings hint at possible individualized therapies for patients with CHF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tokyo CCU Network Scientific Committee, Tokyo, Japan. kenichi-matsushita@umin.ac.jp.
- Department of Cardiology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, Saitama, 350-1298, Japan. kenichi-matsushita@umin.ac.jp.
- Tokyo CCU Network Scientific Committee, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
- Tokyo Metropolitan Government
- Vehicle Racing Commemorative Foundation
Zitieren
APA
Matsushita, K., Harada, K., Miyamoto, T., Iida, K., Yamamoto, Y., Shiraishi, Y., Nagatomo, Y., Yoshino, H., Yamamoto, T., Nagao, K., & Takayama, M. (2024). Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet–cold pattern. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03745-y
Vancouver
Matsushita K, Harada K, Miyamoto T, Iida K, Yamamoto Y, Shiraishi Y, et al. Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet–cold pattern. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03745-y
BibTeX
@article{Matsushita2024,
author = {Matsushita, Kenichi and Harada, Kazumasa and Miyamoto, Takamichi and Iida, Kiyoshi and Yamamoto, Yoshiya and Shiraishi, Yasuyuki and Nagatomo, Yuji and Yoshino, Hideaki and Yamamoto, Takeshi and Nagao, Ken and Takayama, Morimasa},
title = {Prognostic effect of a vasopressin V2 receptor antagonist in acute congestive heart failure patients with hypoperfusion, the wet–cold pattern},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03745-y}
}
EUVIMED